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Condition ab ICD codes Cancer [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [200] [201] [202] [203] [204] [205] [206] [207] ; ICD-10: C00-43, C44-97 HIV/AIDS ICD-8: 07983; ICD-10: B20-B24, Z21 End stage renal disease ICD-8: 792; ICD-10: N185, Z490-492, Z992 Liver disease ICD-8: 570-573; ICD-10: K70-74, K762-767 Serious neurologic disease [340] [341] 344, 348 ; ICD-10: G10-G14, G35-G37, G71, G82 Congenital anomalies/childhood conditions ICD-8: 27309, 313-314, 343, 741-743, 746, 74709, 74719, 74729, 74739; ICD-10 
